Project Grant R21CA301006
Award Date
4/9/25
Completion Date
3/31/27
Dollars Obligated
$170K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This National Cancer Institute (NCI) Project Grant award under the Cancer Research Manpower program (CFDA 93.398) provides $342,144 to The Leland Stanford Junior University from July 1, 2024 to December 31, 2024. The grant supports a 2-year research project and 5-year career development program focused on improving chimeric antigen receptor (CAR) T cell therapies for patients with large B-cell lymphoma (LBCL). The primary research goals are: (1) to define the most therapeutically relevant CAR...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $330,942 over 5 years to The Leland Stanford Junior University to conduct research on improving personalized cellular immunotherapies for cancer patients. The project aims to develop scalable screening methodologies to rapidly assess the performance of various chimeric antigen receptor (CAR) T cell constructs across large cohorts of liquid and solid tumor patients. It...
The National Cancer Institute awarded Dartmouth College a $604,627 Project Grant under the Cancer Biology Research (CFDA 93.396) program to study ways to engineer durable antitumor protection using chimeric antigen receptor (CAR) T cell therapies. The project aims to deconvolve CAR T cell heterogeneity to understand how individual T cell subsets behave in vivo and identify engineering strategies to program CAR stem cell-like (TSCM) and tissue-resident memory (TRM) cell fates. This research could...
This National Cancer Institute (NCI) Project Grant under the Cancer Research Manpower program (CFDA 93.398) will provide $232,878 in funding to The Leland Stanford Junior University to conduct research on next-generation chimeric antigen receptor (CAR) T cell therapies for large B-cell lymphoma (LBCL). The 3-year project aims to: 1) Define the most therapeutically relevant CAR T cell subsets in LBCL patients, and 2) Overcome an immune suppression mechanism of resistance to CAR T cell therapy for...
This Project Grant award of $207,900 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports research at Stanford University to develop a three-cell synthetic immunotherapy system. The project aims to screen combinations of engineered chimeric antigen receptor (CAR) T cells, natural killer (NK) cells, and macrophages to identify receptor pairs that...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $2,785,981 to Celldom Inc. to develop and commercialize a high-throughput platform for analyzing the functional and transcriptional properties of individual CAR-T cells. The goal is to measure key parameters like cytotoxicity, proliferation, cytokine secretion, and gene expression in over 100,000 single CAR-T cells simultaneously, to better...
This $931,841 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support the development of next-generation immunotherapies for pediatric cancers at Stanford University. The award aims to leverage the university's expertise in cellular and molecular immunology, synthetic biology, and protein engineering to create safer and more potent immunotherapies for children's cancers. Key focus areas include overcoming suppressive tumor...
This Project Grant award of $1,220,394 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research will fund a comprehensive research project to investigate the acute and chronic neurotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy. The research aims to deepen the understanding of the neurological complications, known as immune effector cell-associated neurotoxicity syndrome (ICANS), that can occur in...
This $587,108 Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to The Trustees of the University of Pennsylvania aims to enhance the efficacy of non-activated chimeric antigen receptor (CAR) T cell therapies for cancer treatment. The key research activities will: Investigate methods to improve the transduction efficiency and effector function of non-activated CAR T cells by modulating the type I interferon (IFN1) signaling pathway. This includes...
This $627,272 federal Project Grant award from the National Cancer Institute (Cancer Treatment Research, CFDA 93.395) supports research led by The Johns Hopkins University to optimize the efficacy of chimeric antigen receptor (CAR) T-cell therapy against pancreatic tumors. The key objectives are to engineer self-propelled, tumor-infiltrating CAR T-cells using synthetic "velocity receptors" that enhance migration speed and tumor penetration. The project will test the motility and...